Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 18/20 | 0.58 |
| ▸ | CDK2 | P24941 | 18/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 18/20 | 0.58 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781889 | 0.83 | CCNE1 (0.63) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL5783426 | 0.81 | CA9 (0.57) | CCNE1CDK2CDK5SMN1; SMN2MAPT | |
| SCHEMBL5780604 | 0.80 | CCNE1 (0.62) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL5779739 | 0.79 | CCNE1 (0.67) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL5784478 | 0.78 | CDK5 (0.66) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL5780583 | 0.78 | CCNE1 (0.68) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL5779226 | 0.78 | CCNE1 (0.64) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL5780938 | 0.76 | CCNE1 (0.66) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL5781046 | 0.76 | CCNE1 (0.64) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL5779275 | 0.76 | CCNE1 (0.73) | CCNE1CDK2CDK5CDK5R1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1256578-B1 | Thiazole derivatives and their use as cdk inhibitors | PFIZER PROD INC (US) | 2006-01-11 | — | — | EP | claimed |
| US-6720427-B2 | USED TO TREAT ABNORMAL CELL GROWTH AND CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2004-04-13 | — | — | US | claimed |
| US-20030078252-A1 | Thiazole derivatives | PFIZER INC. | 2003-04-24 | — | — | US | claimed |
| EP-1256578-A1 | Thiazole derivatives and their use as cdk inhibitors | Pfizer Products Inc. (US) | 2002-11-13 | — | — | EP | claimed |
| EP-1256578-B1 | Thiazole derivatives and their use as cdk inhibitors | PFIZER PROD INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040192746-A1 | Thiazole derivatives | PFIZER INC | 2004-09-30 | — | — | US | disclosed |
| US-6720427-B2 | USED TO TREAT ABNORMAL CELL GROWTH AND CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030078252-A1 | Thiazole derivatives | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1256578-A1 | Thiazole derivatives and their use as cdk inhibitors | Pfizer Products Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078252-A1 | Thiazole derivatives | CDK1, CDKL1, CDK5 | CCNE1 112/4885CDK2 10/4885CDK5 3/4885 |
| US-20040192746-A1 | Thiazole derivatives | CDK1, CDKL1, CDK5 | CCNE1 112/4885CDK2 10/4885CDK5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.